Xenetic Biosciences reports Q3 net loss of ~$1.4M; cash $19.7M after $12.5M private placement

Xenetic Biosciences, Inc.

2022-Q3 EPS reported -$0.41 revenue$828,088

Net loss ~$1.4M for Q3 2021; R&D expenses up 36.1% to $0.8M, G&A up 17.5% to $0.9M.
Ended Q3 with cash ~$19.7M and working capital ~$19.5M after July $12.5M private placement.
XCART platform progressing toward IND-enabling studies; issued US patent for co-administration with personalized vaccine.
PolyXen royalty income ~$0.3M from Takeda sublicense in Q3; partner Pharmsynthez filed Epolong registration in Russia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.